Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 12OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 113Cyclophosphamide 106pembrolizumab 82Radiotherapy 79Nivolumab 68Cisplatin 67fludarabine 64Carboplatin 59Biopsy 54Standard of Care 46Radiosurgery 43Gemcitabine 43Paclitaxel 42Dexamethasone 41Rituximab 37Radiation 37Doxorubicin 37Blood Specimen Collection 37Cytarabine 36Bevacizumab 35venetoclax 34fludarabine phosphate 33Surveys and Questionnaires 32Temozolomide 31Radiotherapy, Intensity-Modulated 31Capecitabine 31Practice Guidelines as Topic 28Etoposide 28Oxaliplatin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × belzutifan × 30 days × Clear all
NCT07023432 2026-05-22

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

M.D. Anderson Cancer Center

Phase 2 Recruiting
78 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07593040 2026-05-20

Moonlanding

Vall d'Hebron Institute of Oncology

Phase 2 Not yet recruiting
150 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡